The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal DESolve Nx trial reported at EuroPCR 2013. DESolve (Elixir Medical Corporation) is the first bioresorbable PLLA-based polymer scaffold that releases novolimus, a major metabolite of sirolimus. "The degradation time is about one year," explained the lead study author Alexandre Abizaid, Director of Interventional Cardiology at Institute Dante Pazzanese de Cardiologia, São Paulo, Brazil...
-
Source: http://www.medicalnewstoday.com/releases/260912.php
--
Manage subscription | Powered by rssforward.com
24 May, 2013
-
Source: http://www.medicalnewstoday.com/releases/260912.php
--
Manage subscription | Powered by rssforward.com
Post a Comment